• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Pfizer Ltd.
    08 Jul 2025
    5227.00
    1.15%
    Dividend stocks: Pfizer, 6 others to go ex-date on July 9; do you own any?
    Business Standard
    Here is the complete list of stocks that will trade ex-dividend on July 9, following their announcements of dividend rewards for shareholders
    Copy LinkShare onShare on Share on Share on
    Pfizer Ltd. is trading below its 30 day SMA of 5234.7
    logo
    Sun Pharmaceutical Industries Ltd.
    07 Jul 2025
    US FDA Classification
    1616.60
    0.43%
    Sun Pharma says working towards full regulatory resolution at 3 plants facing USFDA action
    Business Line
    The company is facing an import alert for the Halol facility and also is in receipt of non-compliance letter for the Mohali facility
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.
    logo
    Solara Active Pharma Sciences Ltd.
    06 Jul 2025
    677.55
    0.51%
    Solara Active Pharma Sciences: A Strategic Shift Towards High-Value Growth
    Solara Active Pharma Sciences: A Strategic Shift Towards High-Value Growth
    NDTV Profit
    Copy LinkShare onShare on Share on Share on
    Promoters pledged 4.31% of shares in last quarter. Total pledge stands at 38.95% of promoter holdings
    logo
    Emcure Pharmaceuticals Ltd.
    04 Jul 2025
    1348.90
    -2.02%
    Emcure Pharmaceuticals Bulk Deal: BC Investments Offloads Stake For Rs 563 Crore
    Emcure Pharmaceuticals Bulk Deal: BC Investments Offloads Stake For Rs 563 Crore
    NDTV Profit
    The public shareholder sold the 2.37% stake for Rs 1,250.44 apiece.
    Copy LinkShare onShare on Share on Share on
    Emcure Pharmaceuticals Ltd. has gained 42.67% in the last 6 Months
    Emcure Pharma shares dip after 2.4% stake change hands in block trades
    Business Standard | 04 Jul 2025 1 more
    Emcure Pharma Block Deal: Public Shareholder BC Investments To Sell 2.4% Stake
    NDTV Profit | 03 Jul 2025
    logo
    Sun Pharmaceutical Industries Ltd.
    04 Jul 2025
    US FDA Classification
    1616.60
    0.43%
    Price pressures to intensify for drugmakers, says Sun Pharmaceutical
    Business Standard
    Sun Pharma expects global pricing strain due to policy shifts, as FY25 US sales rise 5.8% despite compliance challenges; specialty business lifts overall growth
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical Industries Ltd. is trading above its 30 day SMA of 1613.0
    logo
    Lupin Ltd.
    04 Jul 2025
    2043.40
    2.79%
    Lupin launches nasal spray in US, part of 200-drug pipeline by FY30
    Business Standard
    The product, launched in the US market, is a generic version of Atrovent and part of Lupin's plan to scale complex generics revenue share to 62 per cent by FY30
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.
    Lupin launches generic Ipratropium Bromide nasal spray in US market
    Business Line | 04 Jul 2025
    logo
    Aurobindo Pharma Ltd.
    04 Jul 2025
    1094.40
    -1.33%
    Buy Or Sell: Aurobindo Pharma, LIC Housing Finance On Ajit Mishra's Radar Check Target Price
    Buy Or Sell: Aurobindo Pharma, LIC Housing Finance On Ajit Mishra's Radar Check Target Price
    NDTV Profit
    The stock recommendations carry specific stop loss and target price.
    Copy LinkShare onShare on Share on Share on
    Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1093.6
    logo
    Cipla Ltd.
    04 Jul 2025
    1574.60
    0.88%
    Cipla faces revenue and margin pressure ahead of Revlimid patent expiry
    Cipla faces revenue and margin pressure ahead of Revlimid patent expiry
    Economic Times
    Cipla faces revenue and margin pressure due to the upcoming Revlimid patent expiry, leading to underperformance and analyst downgrades. Margin is expected to drop significantly in FY26 and FY27, with concerns about finding a suitable buyer after Torrent's acquisition of JB Chemicals. While Cipla is pursuing new respiratory and complex generic assets, analysts doubt these will fully offset Revlimid's decline.
    Copy LinkShare onShare on Share on Share on
    Cipla Ltd. is trading above all available SMAs
    logo
    Piramal Pharma Ltd.
    03 Jul 2025
    200.67
    0.25%
    Carlyle Group may sell 10% stake in Piramal Pharma via block deals: Report
    Business Standard
    Piramal Pharma sold 20 per cent of its stake to Carlyle Group in June 2020, in a deal worth 3,523 crore
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 257 to 247 in Jun 2025 qtr
    logo
    Sigachi Industries Ltd.
    03 Jul 2025
    Dividend High Gain High Volume Insider Trades
    42.87
    13.71%
    Sigachi Mishap: Expert panel begins investigation
    Business Line
    The blast occurredon June 30 morning when 143 workers were on duty in the plant of the drug-maker
    Copy LinkShare onShare on Share on Share on
    Sigachi Industries Ltd. is trading at high volume of 192.4M with price gain of 13.71.
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd